GUFICBIO

Gufic Biosciences share price & financials

Price
₹355.25
Market cap
₹4.3k Cr
Sector
Healthcare
Calls analysed
8
Latest concall · Q1 FY27 · call held 17 Aug 2026

Gufic Biosciences Limited Q1 FY27

Revenue ₹260.8 cr +15%EBITDA ₹47.2 cr +42%EBITDA Margin 18.09% PAT ₹22.46 cr +86%

What went well

  • Total revenue from operations in Q1 FY27 was INR260.8 crores, a 14.95% increase from INR226.9 crores in Q1 FY26.
  • EBITDA for Q1 FY27 was INR47.2 crores, marking a 42.17% YoY growth from INR33.2 crores in Q1 FY26.
  • EBITDA margin expanded to 18.09% in Q1 FY27 from 14.6% in Q1 FY26.

What to watch

  • A 10-15 day plant shutdown occurred in Q1 for GLP-1 new machine introduction, impacting initial traction.
  • Current WHO Phase 1 facility limitations restrict botulinum toxin registration to Southeast Asian and African markets, delaying access to other global markets.
Read the full call →

What Gufic Biosciences Limited does

Gufic Biosciences is a research-based pharmaceutical company and one of India's largest manufacturers of lyophilized (freeze-dried) injectable drugs, alongside natural/herbal and nutraceutical formulations. It runs four business lines: branded domestic formulations sold through a large field force across critical-care, women's health/fertility, botulinum toxin (aesthetics and neurology) and pain/GI/nutraceutical categories; contract manufacturing (CMO) of injectables for other pharma companies; bulk drug/API manufacturing (anesthetics, antifungals, antibiotics); and an international business that registers, licenses and exports products worldwide. Manufacturing is spread across dedicated facilities in Navsari (Gujarat), Belgaum (Karnataka) and a newer complex-injectables plant in Indore (Madhya Pradesh) built for regulated markets such as the US and EU.

Segments

  • Domestic Business
  • CMO Business
  • Bulk Drug (API) Business
  • International Business
Manufacturing facilities
4 dedicated plants — Navsari Unit I & II (Gujarat), Belgaum (Karnataka) and Indore (Madhya Pradesh), plus a dedicated Penem/Carbapenem block and a separate API facility
Indore facility installed capacity
60mn lyophilized vials/yr + 120mn liquid ampoules/yr + 72mn liquid vials/yr, built to regulated-market (US/EU) standards
Navsari installed capacity (Units I & II)
48mn lyophilized vials/yr combined + 12mn ampoules/yr + 32.8mn pre-filled syringes/yr, incl. liposomal Amphotericin B and depot injections
Field force
~1,000+ representatives across 8 domestic strategic business units
Domestic reach
100+ SKUs, 30,000+ prescribers, 1,10,000+ retail outlets, 1,20,000+ doctors reached, 80% of tertiary-care hospital coverage
CMO partner base
70+ partner companies, 150+ products manufactured across multiple therapy areas
Founded 1984Headquarters Mumbai, Maharashtra, IndiaEmployees 1,988 (2025-03-31) Company website

Guidance record · Q1 FY27

what the last two calls moved 27 tracked 4 delivered 7 missed 16 open
  • Indore Revenue (FY26) delivered, diluted said Q3 FY25 Promised: Minimum INR 150 crores additional revenue Q1 FY27: Promise for FY26 has been achieved per prior quarter analysis. No further updates.
  • Indore US FDA Action Timeline went quiet said Q2 FY25 Promised: Calendar year 2026 Q1 FY27: No specific mention of the US FDA timeline or inspection trigger.
  • Indore EU Approval Timeline delayed said Q2 FY25 Promised: By end of 2025 Q1 FY27: The Indore certificate... we are just waiting for the feedback from the authority... hopefully, in the next maybe a month or 2, we should be hearing something from them.

All 27 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 15.0%, net profit up 83.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue204 208 205 227 230 +13%231 +11%252 +23%261 +15%
EBITDA39 34 27 32 36 −8%36 +6%46 +70%47 +47%
Net profit22 19 8 12 15 −32%16 −16%21 +163%22 +83%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +14.7% 1Y

₹300₹350₹400₹450Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 17 Nov 2025Q3 FY26 — 16 Feb 2026Q4 FY26 — 1 Jun 2026Q1 FY27 — 17 Aug 2026

1Y: ₹370.7 on 10 Sept 2025 → ₹425.1. High ₹448 (7 Sept 2026), low ₹273.5 (4 Mar 2026).

How the price took the results

close before → close after

Q1 FY27
−0.9%
17 Aug
Q4 FY26
+3.8%
1 Jun
Q3 FY26
−5.3%
16 Feb
Q2 FY26
−1.5%
17 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 10.9% a year over 3 years, FY23 to FY26. Operating margin narrowed to 16.0%.

Year endingFY23FY24FY25FY26
Revenue₹690 Cr₹807 Cr₹820 Cr₹940 Cr
Operating profit₹132 Cr₹144 Cr₹136 Cr₹150 Cr
Operating margin19.1%17.8%16.6%16.0%
Interest₹8 Cr₹15 Cr₹23 Cr₹36 Cr
Depreciation₹21 Cr₹16 Cr₹21 Cr₹32 Cr
Net profit₹79 Cr₹86 Cr₹70 Cr₹64 Cr
Net margin11.4%10.7%8.5%6.8%
Cash from operations₹-27 Cr₹-7 Cr₹123 Cr₹44 Cr
Free cash flow₹-214 Cr₹-116 Cr₹52 Cr₹13 Cr
ROCE23.0%17.0%13.0%12.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr
Reserves₹164 Cr₹259 Cr₹338 Cr₹523 Cr₹619 Cr₹654 Cr
Borrowings₹62 Cr₹64 Cr₹334 Cr₹333 Cr₹369 Cr₹405 Cr
Other liabilities₹157 Cr₹188 Cr₹179 Cr₹227 Cr₹271 Cr₹273 Cr
Total liabilities₹392 Cr₹521 Cr₹861 Cr₹1.1k Cr₹1.3k Cr₹1.3k Cr
Fixed assets₹100 Cr₹115 Cr₹160 Cr₹159 Cr₹495 Cr₹491 Cr
Capital work in progress₹13 Cr₹41 Cr₹170 Cr₹307 Cr₹24 Cr₹22 Cr
Investments₹0 Cr₹0 Cr₹1 Cr₹2 Cr₹3 Cr₹3 Cr
Other assets₹279 Cr₹365 Cr₹531 Cr₹625 Cr₹747 Cr₹826 Cr
Total assets₹392 Cr₹521 Cr₹861 Cr₹1.1k Cr₹1.3k Cr₹1.3k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, the public trimmed −0.45 pp while DIIs added +0.29 pp. The shareholder count shrank 7% to 29,753.

Promoters
72.5%
FIIs
0.5%
DIIs
3.7%
Public
23.4%

Since Jun 2025

  • Public −0.45 pp
  • DIIs +0.29 pp
  • FIIs +0.15 pp

How it drifted, 12 quarters

Over this window promoters fell from 75.0% to 72.5% — −2.5 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 75.0%, FIIs 0.7%, DIIs 1.6%, Public 22.6%.Dec '23: Promoters 72.5%, FIIs 0.5%, DIIs 1.7%, Public 25.3%.Mar '24: Promoters 72.5%, FIIs 0.1%, DIIs 2.2%, Public 25.2%.Jun '24: Promoters 72.5%, FIIs 0.2%, DIIs 2.4%, Public 24.9%.Sep '24: Promoters 72.5%, FIIs 0.2%, DIIs 2.5%, Public 24.8%.Dec '24: Promoters 72.5%, FIIs 0.3%, DIIs 3.0%, Public 24.2%.Mar '25: Promoters 72.5%, FIIs 0.3%, DIIs 3.4%, Public 23.8%.Jun '25: Promoters 72.5%, FIIs 0.3%, DIIs 3.4%, Public 23.8%.Sep '25: Promoters 72.5%, FIIs 0.3%, DIIs 3.7%, Public 23.5%.Dec '25: Promoters 72.5%, FIIs 0.4%, DIIs 3.7%, Public 23.3%.Mar '26: Promoters 72.5%, FIIs 0.4%, DIIs 3.8%, Public 23.2%.Jun '26: Promoters 72.5%, FIIs 0.5%, DIIs 3.7%, Public 23.4%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Gufic Biosciences Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Jayesh Pannalal Choksi 24.62%unchanged
Zircon Teconica Private Limited 20.47%unchanged
Gufic Private Limited 10.16%unchanged
Vipula Jayesh Choksi 10.01%unchanged
Pranav Jayesh Choksi 7.25%unchanged
Motilal Oswal Financial Services Ltd 3.32%unchanged
ICICI Prudential Multicap Fund Mutual fund2.02%−0.10 pp
Jagdish N Master 1.41%unchanged
Motif Hotels LLP 0.00%unchanged
Tricon Enterprises Private Limited 0.00%unchanged
Jal Private Limited 0.00%unchanged
Gaurang Ramniklal Pandya 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in GUFICBIO

Filings to Aug 2026

0 new, 0 added, 1 trimmed, 0 sold out — net −1.00 L shares (−20.0%).

Held by funds
₹17 Cr
1 schemes
Biggest holder
SBI Healthcare Opportunities Fund
₹17 Cr · 0.3% of that fund
SchemeHoldingLast month
SBI Healthcare Opportunities Fund SBI Mutual Fund₹17 Cr−1.00 L

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

0 added, 1 trimmed — net −1.00 L shares (−20.0%)

Funds are sitting on
+92%
vs est. average cost
Held by funds
₹17 Cr
1 schemes · ≈ 0.33% of the company

Shares held by these funds −50%

Aug '23 5.00 L shares Jul '26

What the price assumes

Growth trap

To justify its price of ₹425, this stock must grow earnings at 33% every year for 7 years. Our analysis caps realistic growth at ~-9%. At that growth it is worth ₹48 — downside of 89%.

Growth the price implies
33.1% a year
for 7 years, fading to 4%
It has actually compounded at
-6.8% a year
net profit, FY23–FY26 · EPS -8.5%
The gap
0.4 pp
-89% downside if it only repeats history
Price today ₹425.1 Value at the reference growth ₹47.63

Change the assumptions yourself →

All earnings calls (8)

Read the Q1 FY27 call →

Learn to analyse Gufic Biosciences Limited

Guides on how to read this kind of business and the numbers that matter.